Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 318 participants.
Also called NCT05503953
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 318 participants
- Registry
-
NCT05503953
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05503953. Randomized; double masking; primary purpose treatment. Start 2022-09-13 (actual); primary completion 2025-06-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
- Condition
- Essential Hypertension
- Intervention (Drug)
- AGSAVI
- Intervention (Drug)
- AGLS
- Lead sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
- Collaborator
- Daehwa Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05503953- Content hash
64f62c803a129b889a29e157d93b6c4ff3b1fbcebf9b40e74839bbda0c085733